Advertisement

Topics

Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor

07:25 EST 10 Nov 2017 | RTTNews

Bristol-Myers Squibb Co. (BMY) on Friday announced updated results for Opdivo (nivolumab) plus BMS-986205, a selective, once-daily oral indoleamine 2,3-dioxygenase 1 (IDO1) inhibitor from the ongoing Phase 1/2a dose escalation and expansion study, CA017-003.

Original Article: Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor

NEXT ARTICLE

More From BioPortfolio on "Bistol-Myers: Encouraging Response Observed With Opdivo Plus IDO1 Inhibitor"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...